|
1. Biologie
|
|
|
Missing the Soil for the Seeds in Cancer Research [Scientific American]
|
|
|
|
|
|
Researchers
and pharmaceutical companies study cancer in Petri dishes or mice, but
neither recreates the behavior of patient cells accurately. Therefore,
new drugs often look promising in preclinical trials, but frequently
fail when tested on patients because the “soil factor” is not taken into
account. Engineers may help with this.
|
|
|
|
|
|
|
3.1 Tabac
|
|
|
|
4.5 Dép., diag. & prono. - Colorectal
|
|
|
Over fifty per cent do not go for new bowel cancer test [Cancer Research UK]
|
|
|
|
|
|
The
NHS Bowel Scope Screening Programme (link is external) offers a one-off
test to 55-year-olds that involves a specially trained nurse or doctor
using a flexible tube, with a tiny camera on the end, to look inside the
large bowel. The test helps prevent bowel cancer by finding and
removing pre-cancerous polyps.
|
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
|
Acute Myeloid Leukemia [Now@NEJM]
|
|
|
|
|
|
Many
recent biologic insights have shed light on the nosology of acute
myeloid leukemia. Although this new knowledge has not yet had a major
influence on the treatment of the disease, strategies under
investigation may improve outcomes. A new review article summarizes.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
CICON2015 Report from Day 3 [CRI]
|
|
|
|
|
|
Today’s
sessions at the inaugural International Cancer Immunotherapy Conference
focused on four main areas: viruses and cancer; biomarkers; imaging
immune responses; and the microbiome.
|
|
|
|
|
|
|
CICON2015 Report from Day 4 [CRi]
|
|
|
|
|
|
Much
of this conference has focused on using immunotherapy to treat cancer.
Today, we heard from several investigators who are working on the other
end of the equation: developing ways to prevent cancer. This includes
what many consider to be the holy grail of medicine: a preventive cancer
vaccine.
|
|
|
|
|
|
|
CICON2015 Report from Day 2 [CRI]
|
|
|
|
|
|
Not
all CARs are the same in terms of how they are built, and there seem to
be important therapeutic consequences as a result. June has shown that
in CLL patients treated with CAR T cells made with a certain internal
bit of machinery called a 4-1BB domain can persist in patients for at
least 4 years.
|
|
|
|
|
|
|
CICON2015 Report from Day 1 [CRI]
|
|
|
|
|
|
Following
introductory remarks by Jill O’Donnell-Tormey, Ph.D., CRI’s CEO and
director of scientific affairs, the conference kicked off with a keynote
address by one of the field’s pioneers. This opening salvo was followed
by back-to-back plenary sessions devoted to two of the hottest areas in
immunotherapy: checkpoint blockade biology and identifying genetic
targets for immunotherapies.
|
|
|
|
|
|
|
Reality Check: Cancer Experts Discuss Hurdles Facing CAR-T Therapy [Xconomy]
|
|
|
|
|
|
Even
if the clinical and regulatory challenges are met, and products come to
market, their owners are likely to face a big commercial problem that’s
more familiar to the consumer technology world: Constant new iterations
of products. Put another way, CAR-T cells could be the iPhones of the
biotech world.
|
|
|
|
|
|
|
Are Engineered Small Proteins the Next-generation Immune Checkpoint Inhibitors? [CANCER RESEARCH Catalyst]
|
|
|
|
|
|
There
are, however, some limitations to using the high-affinity PD-1 proteins
in patients in their current form, the researchers note. Because of
their small size, the high-affinity PD-1 proteins may get excreted from
the body more quickly, which means that they would have to be
administered more frequently than antibodies. Further, they may be
“immunogenic,” meaning patients could develop an immune response to the
drug itself.
|
|
|
|
|
|
|
To PD-L1 or Not to PD-L1: That Is the Question [Cancer Commons]
|
|
|
|
|
|
Excluding
PD-L1-negative patients from trials of immune checkpoint inhibitors
appears to be a fallacy. Ignoring many other possibilities, it is
entirely probable that because of the shortcomings of reagents, and the
elusive nature of PD-L1, many PD-L1-negative tumors may be
‘false-negative‘; they really do express enough PD-L1 to respond to
immune checkpoint drugs.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
How the U.S. could cure rising drug prices [Fortune]
|
|
|
|
|
|
Across
the universe of these drugs, prices are rising faster than benefits. In
1995 the average cost of using a cancer drug to deliver a “life year”
of benefit to a patient was around $50,000 in current dollars; today
that precious year costs about $225,000.
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
|
6.11 Patients
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
|